Funding
Imperial College spin-out PolyTherics Ltd, has closed a £3 million round led by Imperial Innovations Group plc and including Longbow Capital and The Capital Fund. This follows on from a £2.3 million financing backed by the same syndicate in June 2007.
PolyTherics has developed technologies to improve the properties of biologic drugs and has licensed its targeted PEGylation technology TheraPEG to several commercial partners.
The new money will be used for the further development of the company’s PEGylation drug delivery platforms, HiPEG and CyPEG.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
